

*Prelim*  
*2A*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

|   |   |
|---|---|
| <p>In re Application of<br/>Goeddel et al.</p> <p>Serial No.: To be assigned</p> <p>Filed: May 26, 2000</p> <p>For: TRAF INHIBITORS</p> | <p>Group Art Unit: To be assigned</p> <p>Examiner: To be assigned</p> |
|---|---|

**PRELIMINARY AMENDMENT**

Assistant Commissioner of Patents  
Washington, D.C. 20231

Sir:

This Preliminary Amendment is being filed concurrently with Applicants' Rule 53(b) Continuation Application. Applicants respectfully request entry of the following preliminary amendment prior to examination on the merits.

**In the Specification:**

On page 3, lines 12-14, delete "U.S. application Serial No. 08/446,915 filed 22 May 1995 which is a continuation-in-part of application Serial No. 08/331,394 filed 28 October 1994 which, in turn, is a continuation-in-part of application Serial No. 08/250,858 filed 27 May 1994" and insert -- US Patent Nos. 5,670,319 issued September 23, 1997 and 5,708,142 issued January 13, 1998 --.

On page 7, please delete the text on line 9, and insert therefor -- Figures 4A-C illustrate the inhibitory effect of I-TRAF on activation of NF-KB. Figure 4A shows that I-TRAF inhibits TRAF2-mediated NF-KB activation in a dose-dependent manner. Figures 4B and 4C show that NF-KB activation through both TNFR2 and CD40 is similarly blocked by increased expression of I-TRAF--.